The heart is in the disaster area, and the peak pharmacy is in action.
Release time:
2020-08-21
is a disaster area. Jianfeng Pharmacy is in action
. News from our newspaper 8# May 13 . Xiang Shunjiao, general manager of Jianfeng Pharmacy, transferred the donations of employees to the head of Yongkang Tianzhi Tang Pharmacy, and sent 2 drugs donated by Chongqing Heping Pharmaceutical Co., Ltd. to Jianfeng Tianzhi Tang Pharmacy and Jianfeng No.4 Pharmacy with trucks respectively. In the early morning of December 4 , typhoon
4this year "hegby " landed in yueqing, Wenzhou, and passed through pan 'an county, Jinhua city at 10 on the same day. Yongkang City, which is adjacent to Pan'an County, has also been greatly affected. River water is drained into the city. The Gushan area is seriously waterlogged, and many shops in the streets are flooded, causing heavy losses. Yongkang Tianzhitang Pharmacy, a big pharmacy located on the riverside of Gushan Town, was also hit hard by the flood. The entire store was flooded, the drugs in the store were destroyed, and the loss was incalculable. It is in urgent need of post-disaster reconstruction. 8# On the morning of April 5 , Xiang Shunjiao, general manager of Jianfeng Pharmacy, and Zhuang Linfang, deputy general manager, rushed to the disaster-stricken area of Gushan, Yongkang to visit their subordinate drugstores, understand the actual situation of the drugstores after the disaster, and report the current disaster situation of Jianfeng Pharmacy to the relevant departments of Yongkang City to strive for favorable support policies for post-disaster reconstruction for drugstores.
If one side is in trouble, all sides will support. In order to encourage Jianfeng Tianzhi Hall Pharmacy to rebuild its store and help it resume its operation as soon as possible, on August 28, August 29, the headquarters of the pharmacy issued"Natural Disaster Ruthless, Jianfeng Love -
Donation Proposalto Jianfeng Tianzhi Hall Disaster" to all employees, calling on all party members and department heads to take the lead in donating money and collect it in a unified way, unified reporting, the headquarters regularly publishes the donation catalogue in the WeChat group of the management team of the peak pharmacy, so as to make the donation real-name, open and transparent. This public donation raised a total of 13108 yuan. (Lang Minxiao)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page